Recent Updates
Recently added Catalysts

MK0524

Phase 2

Seasonal Allergies | Small molecule | Other |Merck & Company, Inc.|Last Updated: Dec 22, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment766
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00533208MK0524 Seasonal Allergic Rhinitis Study (0524-005)(COMPLETED)PHASE2 COMPLETED 766Jul 1, 2003Oct 1, 2003Dec 22, 2015 -
Unlock Drug Trial Details
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
MK0524DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 75 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Person has had at least 2 years of seasonal allergies * Person has had a positive skin test to at least 1 of the allergens of the season * Person is a non-smoker Exclusion Criteria: * Person has been hospitalized within the last 4 weeks * Person is a female who has had a bab...

Unlock Eligibility Criteria